Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

INTRODUCTION: Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present pharmacokinetic (PK), efficacy, and safety results from pediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Upadhyaya, Himanshu P., Chien, Jenny Y., Long, Amanda J., Bohm, Martin S., Kallewaard, Nicole L., Macpherson, Lisa F., Patel, Dipak R., Hufford, Matthew M., Krull, Constance J., Ang, Jocelyn Y., Chen, Peter, Muller, William J., Potts, Jeffrey A., Quinn, Timothy, Williams, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390421/
https://www.ncbi.nlm.nih.gov/pubmed/37329415
http://dx.doi.org/10.1007/s40121-023-00832-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390421/
https://www.ncbi.nlm.nih.gov/pubmed/37329415
http://dx.doi.org/10.1007/s40121-023-00832-y

Ejemplares similares